{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:20:52Z","timestamp":1787775652356,"version":"build-2784847793"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This is a retrospective cohort study over 20 years (1990\u20132013) that included all patients with biopsy-proven lupus nephritis (LN) followed up at our nephrology department. We aimed to determine the clinicobiologic predictors of flare-up of LN. Flare was defined as an increase in systemic lupus erythematosus (SLE) disease activity index (SLEDAI) score of at least four points. Clinical manifestations and laboratory parameters were assessed and the SLEDAI score was determined for each patient. We included patients with SLE who fulfilled at least four of the American College of Rheumatology criteria for the classification of SLE. A total of 249 patients including 227 females and 22 males with a median age at diagnosis of 34.32 years (range 16\u201369) were studied. The mean follow-up duration was 122.4 \u00b1 27 months. Renal symptoms included hypertension in 40%, nephrotic syndrome in 30%, and renal failure in 69.4% of the cases. Class IV and class III nephritis (ISN\/RPS) were observed in 44.9% and 24% of the patients, respectively. On univariate analysis, flare predictors were age &lt;30 years (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02), lymphocytopenia (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002), the presence of diffuse proliferative LN (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009), and discontinuation of immunosuppressive therapy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004). Our study suggests that these markers should be monitored routinely as prognostic parameters in SLE to characterize patients who are at risk and who should be followed more closely.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/1319-2442.220863","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T23:35:26Z","timestamp":1513640126000},"page":"1349-1355","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Factors Associated with Relapse of Lupus Nephritis"],"prefix":"10.4103","volume":"28","author":[{"given":"Meriam","family":"Hajji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Harzallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayet","family":"Kaaroud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Barbouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fethi Ben","family":"Hamida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taieb Ben","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20260302","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/ki.1996.528","article-title":"\u201cNephritic flares\u201d are predictors of bad long-term renal outcome in lupus nephritis","volume":"50","author":"Moroni","year":"1996","journal-title":"Kidney Int"},{"key":"R2-13-20260302","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-13-20260302","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"R4-13-20260302","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial","volume":"125","author":"Gourley","year":"1996","journal-title":"Ann Intern Med"},{"key":"R5-13-20260302","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1523-1755.2000.00832.x","article-title":"Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide","volume":"57","author":"Ioannidis","year":"2000","journal-title":"Kidney Int"},{"key":"R6-13-20260302","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/ndt\/gfm245","article-title":"The long-term outcome of 93 patients with proliferative lupus nephritis","volume":"22","author":"Moroni","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R7-13-20260302","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1046\/j.1523-1755.2002.00280.x","article-title":"Renal flares in 91 SLE patients with diffuse proliferative glome-rulonephritis","volume":"61","author":"Mosca","year":"2002","journal-title":"Kidney Int"},{"key":"R8-13-20260302","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/art.1780391212","article-title":"Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide","volume":"39","author":"Ciruelo","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R9-13-20260302","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"key":"R10-13-20260302","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for longterm immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R11-13-20260302","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/art.10142","article-title":"Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies","volume":"46","author":"Illei","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R12-13-20260302","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"R13-13-20260302","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1191\/0961203304lu2023oa","article-title":"Review of ACR renal criteria in systemic lupus erythematosus","volume":"13","author":"Dooley","year":"2004","journal-title":"Lupus"},{"key":"R14-13-20260302","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"15","author":"Weening","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R16-13-20260302","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1373\/clinchem.2012.184259","article-title":"The Kidney Disease Improving Global Outcomes (KDIGO) guideline update for Chronic Kidney Disease: Evolution not revolution","volume":"59","author":"Lamb","year":"2013","journal-title":"Clin Chem"},{"key":"R17-13-20260302","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/ndt\/gfm833","article-title":"Distribution of pathologic findings in individuals with nephrotic proteinuria according to serum albumin","volume":"23","author":"Gupta","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R18-13-20260302","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"R19-13-20260302","doi-asserted-by":"crossref","first-page":"c92","DOI":"10.1159\/000085054","article-title":"Mycophenolate mofetil for remission induction in severe lupus nephritis","volume":"100","author":"Cross","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"R20-13-20260302","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1191\/0961203306lu2271oa","article-title":"Sustained remission of lupus nephritis","volume":"15","author":"Barber","year":"2006","journal-title":"Lupus"},{"key":"R21-13-20260302","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0272-6386(00)70262-9","article-title":"Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group","volume":"35","author":"Korbet","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"R22-13-20260302","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1191\/0961203305lu2081oa","article-title":"Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine","volume":"14","author":"Chan","year":"2005","journal-title":"Lupus"},{"key":"R23-13-20260302","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1191\/0961203303lu340oa","article-title":"Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone","volume":"12","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2003","journal-title":"Lupus"},{"key":"R24-13-20260302","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/art.1780340802","article-title":"Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study","volume":"34","author":"Petri","year":"1991","journal-title":"Arthritis Rheum"},{"key":"R25-13-20260302","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/art.10138","article-title":"Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine","volume":"46","author":"Mok","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R26-13-20260302","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJM197811232992102","article-title":"Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide","volume":"299","author":"Donadio","year":"1978","journal-title":"N Engl J Med"},{"key":"R27-13-20260302","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0961203308100481","article-title":"European consensus statement on the terminology used in the management of lupus glomerulo-nephritis","volume":"18","author":"Gordon","year":"2009","journal-title":"Lupus"},{"key":"R28-13-20260302","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1191\/0961203303lu444oa","article-title":"Relapses of lupus nephritis: Incidence, risk factors, serology and impact on outcome","volume":"12","author":"El Hachmi","year":"2003","journal-title":"Lupus"},{"key":"R29-13-20260302","first-page":"1","article-title":"Renal flare prediction and prognosis in lupus nephritis Hispanic patients","volume":"10","author":"Meja-Vilet","year":"2015","journal-title":"Lupus"},{"key":"R30-13-20260302","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/rheumatology\/39.12.1316","article-title":"Prog-nostic parameters for flare in systemic lupus erythematosus","volume":"39","author":"Mirzayan","year":"2000","journal-title":"Rheumatology (Oxford"},{"key":"R31-13-20260302","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"R32-13-20260302","first-page":"2239","article-title":"Serologically active clinically quiescent systemic lupus erythematosus - Predictors of clinical flares","volume":"21","author":"Walz LeBlanc","year":"1994","journal-title":"J Rheumatol"},{"key":"R33-13-20260302","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0049-0172(05)80023-X","article-title":"Course and prognostic value of systemic lupus erythematosus disease activity index in black Caribbean patients","volume":"23","author":"Nossent","year":"1993","journal-title":"Semin Arthritis Rheum"},{"key":"R34-13-20260302","first-page":"907","article-title":"Predictors of one year outcome in lupus nephritis: The importance of renal biopsy","volume":"81","author":"Esdaile","year":"1991","journal-title":"Q J Med"},{"key":"R35-13-20260302","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2004050350","article-title":"Glomerular podocytopathy in patients with systemic lupus erythematosus","volume":"16","author":"Kraft","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R36-13-20260302","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrneph.2012.220","article-title":"Diagnosis and treatment of lupus nephritis flares - An update","volume":"8","author":"Sprangers","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"R37-13-20260302","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1191\/0961203305lu2059oa","article-title":"Lupus nephritis flares","volume":"14","author":"Sidiropoulos","year":"2005","journal-title":"Lupus"},{"key":"R38-13-20260302","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/art.1780170602","article-title":"A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis","volume":"17","author":"Steinberg","year":"1974","journal-title":"Arthritis Rheum"},{"key":"R39-13-20260302","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: The euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R40-13-20260302","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"}],"container-title":["Saudi Journal of Kidney Diseases and Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00936703-201728060-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:37:46Z","timestamp":1787773066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00936703-201728060-00013"}},"subtitle":["A Single Center Study of 249 Cases"],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/1319-2442.220863","relation":{},"ISSN":["1319-2442"],"issn-type":[{"value":"1319-2442","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}